Latest Episodes
42
Episode 42: Diana Azzam, PhD, Assistant Professor at Florida International University, Co-Founder at First Ascent Biomedical
“Our studies are open for those that have exhausted standard of care, and we're showing improved responses, and the data is promising. So, I...
38
Episode 41: Craig Serra, Head of Clinical Research Scientific and Technical Engagement, Flatiron Health
"It's amazing how many companies there are and how many opportunities for a kind of a match between a human that needs some help...
40
Episode 40: Professor Justin Stebbing, Editor-in-Chief, Oncogene journal
"I learned very early on that the stupidest cancer cell was cleverer than the cleverest oncologist." - Justin Stebbing, Editor-in-Chief of Oncogene, previously the...
39
Episode 39: Dr. Keith Flaherty, Director of Clinical Research at Massachusetts General Hospital Cancer Center
"Technologies have changed enormously in terms of how we can basically procure, preserve, and then interrogate a tumor specimen...like effectively in real time, like...
38
Episode 38: Dr. Ole Isacson, Professor of Neurology and Neuroscience, Harvard Medical School
"Artificial Intelligence is a tool that really levels up and creates almost like an equity for everybody to participate and, when used effectively, to...
37
Episode 37: Will Greene, Prader-Willi Syndrome patient advocate, Healthcare Engagement Lead at Roche
"The history of rare disease drug development indicates that once you start looking harder for cases, you often tend to find them." - Will...